Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Neurological Biomarkers Market?

In the past few years, the market size for neurological biomarkers has experienced a swift expansion. It is set to rise from $10.7 billion in 2024 to $11.92 billion in 2025, with the compound annual growth rate (CAGR) figuring at 11.4%. The expansion during the historical period can be credited to factors such as the rising incidence of neurological conditions, an aging demographic, the necessity for drug evolution, heightened funding towards neurological studies, and the shift towards personalized medicine.

Expect a swift expansion in the neurological biomarkers market in the coming years, with its value projected to hit $19.91 billion in 2029, growing at a compound annual growth rate (CAGR) of 13.7%. This predicted growth during the forecast period can be credited to factors like early detection biomarkers, the use of biosensors, adoption of wearable devices, worldwide health programs, and a patient-centered approach. Noteworthy trends in the forecast period encompass technological revolutions in imaging, fast-paced improvements in omics technologies, the incorporation of artificial intelligence (AI), the use of real-world evidence in biomarker validation, advancements in diagnostic technologies, and partnerships between the industry and research institutions.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp

What Drivers Are Accelerating Expansion Of The Neurological Biomarkers Market?

The escalating occurrence of neurological disorders is predicted to stimulate the expansion of the neurological biomarker market in the future. Neurological conditions influence the brain, spinal cord, and all other nerves throughout the body. Parkinson’s disease, a neurodegenerative ailment, impacts the neurological system and parts of the body governed by the nerves. Neurological biomarkers play a critical role in offering early diagnoses of Parkinson’s disease through pathological, biochemical, and genetic examinations. For example, the Parkinson’s Foundation, a non-profit organization based in the US, reported in December 2022 that the count of new Parkinson’s disease diagnoses skyrocketed to 90,000 in 2022 from 60,000 annually in 2021. Consequently, the rising prevalence of neurological diseases is fueling the expansion of the neurological biomarker market.

What Are The Key Segment Trends Observed In The Neurological Biomarkers Market?

The neurological biomarkersmarket covered in this report is segmented –

1) By Product: Proteomics Biomarker; Genomics Biomarker; Metabolomics Biomarker; Imaging Biomarker; Other Products

2) By Application: Alzheimer’s Disease; Parkinson’s Disease; Huntington’s Disease; Schizophrenia; Depression; Multiple Sclerosis; Spinal Muscular Atrophy

3) By End-User: Hospital Laboratories; Clinical Diagnostic Centers; Research Organizations; Other End-Users

Subsegments:

1) By Proteomics Biomarker: Protein Biomarkers; Antibody Biomarkers

2) By Genomics Biomarker: DNA Biomarkers; RNA Biomarkers

3) By Metabolomics Biomarker: Metabolite Biomarkers; Lipid Biomarkers

4) By Imaging Biomarker: MRI Biomarkers; PET Scan Biomarkers

5) By Other Products: Neuroinflammatory Biomarkers; Neurotransmitter Biomarkers

Which Long-Term Trends Will Play A Crucial Role In The Neurological Biomarkers Market?

Key players in the neurological biomarkers market are strengthening their market positions and advancing product innovation through strategic partnerships and collaborations. These affiliations are driving innovation in the sector by drawing on shared knowledge and expertise, thereby speeding up the development and launch of cutting-edge therapies. For example, NeuroSense Therapeutics Ltd., an Israeli firm specializing in therapies for aggressive neurodegenerative diseases, formed an alliance with NeuraLight, another Israeli company focusing on precise biomarkers for neurological conditions, in July 2022. In this collaboration, AI and Machine Learning technologies are being used to identify oculometric indicators for Amyotrophic Lateral Sclerosis (ALS). This partnership follows on the heels of NeuraLight’s successful $25 million Series A funding round, and aims to enhance the detection and use of digital ALS indicators in a simultaneous study. This collaboration’s first clinical test is slated to be delivered through this initiative. The alliance places great emphasis on oculometric digital indicators to potentially enable patient stratification and improve the success rates of clinical trials.

Who Are The Major Stakeholders Operating In The Neurological Biomarkers Market?

Major companies operating in the neurological biomarkers market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

What Regional Factors Are Accelerating Growth In The Neurological Biomarkers Market?

North America was the largest region in the neurological biomarkers market in 2024. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12677&type=smp

Browse Through More Reports Similar to the Global Neurological Biomarkers Market 2025, By The Business Research Company

Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Rare Neurological Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Neurology Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model